Back to search

Japan· JP-3959421A1023

エラペグアデマーゼ(遺伝子組換え)

A medicinal product containing エラペグアデマーゼ(遺伝子組換え), registered in Japan by 帝人ファーマ, on the national reimbursement list.

On Japan’s NHI price list

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedエラペグアデマーゼ(遺伝子組換え)ATC—REGISTER NO.JP-3959421A1023PACKS LISTED0CHECKEDSeptember 25, 2026

The record

At a glance

MHLW / PMDA (Japan)
Active substance
エラペグアデマーゼ(遺伝子組換え)
Manufacturer
帝人ファーマ
Country
Japan (JP)
ATC code
—
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

エラペグアデマーゼ(遺伝子組換え) in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All エラペグアデマーゼ(遺伝子組換え) products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6440170c-e778-4beb-9939-266f11e1b9ae
GET /v1/drugs/6440170c-e778-4beb-9939-266f11e1b9ae?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "2.4mg1.5mL1瓶",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "3959421A1023",
  "category": "注射薬",
  "price_yen": 862022,
  "generic_name": "エラペグアデマーゼ(遺伝子組換え)",
  "product_name_jp": null,
  "therapeutic_class": "3959",
  "transitional_expiry": null
}

See everything about エラペグアデマーゼ(遺伝子組換え).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.